BioCryst Pharmaceuticals Inc (BCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
BioCryst Pharmaceuticals Inc (BCRX) P/E Ratio & Valuation History
BioCryst Pharmaceuticals (BCRX) trades at 4.4x trailing earnings and 2.0x sales. Its P/S of 2.0x is below its 5-year median of 3.7x. Its forward P/E is 12.9x. The median P/E across 12 similar companies is 10.7x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 65.9% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 4.4x |
| Forward P/E | 12.9x |
| Price to sales | 2.0x |
| Price to FCF | 5.2x |
| EV/FCF | 6.0x |
| PEG | N/A |
| FCF yield | 19.2% |
Historical Medians
Against its 10-year medians, its P/S is 81.1% below 10.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.0x | 3.7x | 10.6x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 1.9x in 2025 to 71.1x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $7.80 | 5.9x | 1.9x | N/A |
| 2024 | $7.52 | N/A | 3.4x | N/A |
| 2023 | $5.99 | N/A | 3.5x | N/A |
| 2022 | $11.48 | N/A | 7.9x | N/A |
| 2021 | $13.85 | N/A | 15.8x | N/A |
| 2020 | $7.45 | N/A | 71.1x | N/A |
| 2019 | $3.45 | N/A | 9.0x | 11.8x |
| 2018 | $8.07 | N/A | 39.4x | 18.0x |
| 2017 | $4.91 | N/A | 17.3x | 5.8x |
| 2016 | $6.33 | N/A | 17.7x | 295.9x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BCRX
What is BCRX's forward P/E ratio?
BioCryst Pharmaceuticals has a forward P/E ratio of 12.9x.
Is BCRX stock overvalued?
GNG's valuation label for BCRX is Undervalued. Its P/E of 4.4x compares with a median of 10.7x across 12 similar companies.
What is BCRX's price to sales ratio?
BioCryst Pharmaceuticals has a price to sales ratio of 2.0x.
BCRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts